Neil W. A. McGowan
Scottish National Blood Transfusion Service
17 Papers
114 Citations
Neil W. A. McGowan is an academic researcher from Scottish National Blood Transfusion Service. The author has contributed to research in topics: Transplantation & Liver disease. The author has an hindex of 10, co-authored 17 publications. Previous affiliations of Neil W. A. McGowan include Edinburgh Royal Infirmary.
Chat about Author
Papers
Safety profile of autologous macrophage therapy for liver cirrhosis.
Francesca Moroni,Benjamin J. Dwyer,Catriona Graham,Chloe Pass,Laura Bailey,Lisa Ritchie,Donna Mitchell,Alison Glover,Audrey Laurie,Stuart Doig,Emily Hargreaves,Alasdair R. Fraser,Marc Turner,John D.M. Campbell,Neil W. A. McGowan,Jacqueline Barry,Joanna Moore,Peter C. Hayes,Diana Julie Leeming,Mette Juul Nielsen,Kishwar Musa,Jonathan A. Fallowfield,Stuart J. Forbes +22 more
TL;DR: A first-in-human, phase 1 dose-escalation trial demonstrates the safety and feasibility of autologous macrophage therapy in adults with liver cirrhosis and provides a rationale for efficacy studies in cir rhosis and other fibrotic diseases.
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
Philip N. Newsome,Philip N. Newsome,Richard Fox,Richard Fox,Andrew King,Andrew King,Darren Barton,Darren Barton,Nwe-Ni Than,Nwe-Ni Than,Joanna Moore,Chris Corbett,Sarah Townsend,James Thomas,Kathy Guo,Kathy Guo,Diana Hull,Diana Hull,Heather A Beard,Jacqui Thompson,Anne P.M. Atkinson,Carol Bienek,Neil W. A. McGowan,Neil Guha,John D.M. Campbell,Dan Hollyman,Deborah Stocken,Christina Yap,Stuart J. Forbes +28 more
TL;DR: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events compared with standard care.
143
Generation of Functional Beta-Like Cells from Human Exocrine Pancreas
Maria João Lima,Kenneth R. Muir,Hilary M. Docherty,Neil W. A. McGowan,Shareen Forbes,Yves Heremans,Harry Heimberg,John Casey,Kevin Docherty +8 more
TL;DR: It is shown here that overexpression of exogenous Pax4 in combination with suppression of the endogenous transcription factor ARX considerably enhances the production of functional insulin-secreting β-like cells with concomitant suppression of α-cells.
Human umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization
Shareen Forbes,Andrew R Bond,Kayleigh L. Thirlwell,Kayleigh L. Thirlwell,Paul Burgoyne,Paul Burgoyne,Paul Burgoyne,Kay Samuel,June Noble,Gary Borthwick,David Colligan,Neil W. A. McGowan,Philip J. Starkey Lewis,Alasdair R. Fraser,Joanne C. Mountford,Roderick N. Carter,Nicholas M. Morton,Marc Turner,Gerard J. Graham,John M. Campbell,John M. Campbell +20 more
TL;DR: The immunosuppressive and proregenerative properties of HUCPVCs demonstrated long-term positive effects on graft function in vivo, indicating that they may improve long- term human islet allotransplantation outcomes.
43
Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis.
Alasdair R. Fraser,Chloe Pass,Paul Burgoyne,Anne P.M. Atkinson,Laura Bailey,Audrey Laurie,Neil W. A. McGowan,Akib Hamid,Joanna Moore,Benjamin J. Dwyer,Marc Turner,Marc Turner,Stuart J. Forbes,John D. M. Campbell,John D. M. Campbell +14 more
TL;DR: This is the first report of validation of a large-scale, fully Good Manufacturing Practice–compliant, autologous macrophage cell therapy product for the potential treatment of cirrhosis, and shows that the cell product in excipient is remarkably robust, consistently passing the viability and phenotypic release criteria up to 48 hours after harvest.
41